Indore Online Journal

Malignant Pleural Mesothelioma Overview

Inhaled asbestos fibers can cause mesothelioma, an uncommon but deadly malignant tumor that develops in the lining of the heart, abdomen, or lungs. The most prevalent variety of mesothelioma, accounting for 80 to 90% of all identified cases, is pleural mesothelioma, a cancer of the pleura, the mesothelium enclosing the lungs. Males are more likely to be diagnosed with mesothelioma since they are exposed to asbestos more frequently.

Asbestos exposure is the greatest risk factor for developing pleural mesothelioma. A category of minerals known as asbestos can be found in nature as bundles of minute fibers. In many places of the world, soil and rocks contain these fibers. Inhaled asbestos fibers have the potential to enter the lungs. The small airways’ ends, the pleural lining of the lung, and the chest wall can all be reached by fibers that remain in the lungs. Mesothelioma typically affects elderly individuals due to its lengthy latency period, ranging from 20 to 50 years after a person is initially exposed to asbestos (i.e. people age 60 years and older).

DelveInsight’s “Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Malignant Pleural Mesothelioma, historical and forecasted epidemiology as well as the Malignant Pleural Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Malignant Pleural Mesothelioma Market Report: 

• The Malignant Pleural Mesothelioma market size was estimated at USD 690 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)  
• There are four primary types of mesothelioma that can be based on tumor location, wherein pleural mesothelioma and peritoneal mesothelioma are the two most common types of mesothelioma 
• The total Incident cases of Malignant Pleural Mesothelioma in the 7MM were 23,431 in 2021 
• Mesothelioma incidence rates in most of the 7MM countries (except Spain and Japan) are in the declining trend due to reduced population-wide exposure to asbestos 
• In EU-5 countries, the highest number of incident cases of Malignant Pleural Mesothelioma was found in the United Kingdom, with 5,465 cases in 2021 
• Key Malignant Pleural Mesothelioma Companies: Oncovir, Inc., NovoCure Ltd., Virttu Biologics Limited, Aduro Biotech, Inc., Eli Lilly and Company, Kissei Pharmaceutical Co., Ltd., and others 
• Key Malignant Pleural Mesothelioma Therapies: MTG201, Pemetrexed, Celecoxib, cisplatin, pemetrexed, NGR-hTNF, Gemcitabine, and others 
• The Malignant Pleural Mesothelioma epidemiology based on gender analyzed that males are more frequently diagnosed with MPM compared to females

Request a sample for the Malignant Pleural Mesothelioma Market Report 

Key benefits of the Malignant Pleural Mesothelioma Market report:

1. Malignant Pleural Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Pleural Mesothelioma Epidemiology and Malignant Pleural Mesothelioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Malignant Pleural Mesothelioma market report provides insights on the current and emerging therapies.
3. Malignant Pleural Mesothelioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Malignant Pleural Mesothelioma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Malignant Pleural Mesothelioma market.

Discover more about therapies set to grab major Malignant Pleural Mesothelioma market share @ Malignant Pleural Mesothelioma market forecast 

Malignant Pleural Mesothelioma Epidemiology Segmentation:

The Malignant Pleural Mesothelioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Malignant Pleural Mesothelioma
• Prevalent Cases of Malignant Pleural Mesothelioma by severity
• Gender-specific Prevalence of Malignant Pleural Mesothelioma
• Diagnosed Cases of Episodic and Chronic Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma Market  

The dynamics of the Malignant Pleural Mesothelioma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Celecoxib, Cisplatin, and others during the forecasted period 2019-2032.

“The understanding of molecular pathogenesis and the immunological tumor microenvironment have increased recently, among other developments. Additionally, the number of clinical research looking into systemic treatments for Malignant Pleural Mesothelioma keeps growing. Immune checkpoint inhibitor immunotherapy, either alone or in conjunction with other immunotherapies and non-immunotherapies, is the main focus of these trials. Therefore, significant advancements in therapeutics, pathophysiology and diagnosis have been accomplished, all of which are anticipated to have an impact on the future Malignant Pleural Mesothelioma therapeutic market.”

Download the report to understand which factors are driving Malignant Pleural Mesothelioma epidemiology trends @ Malignant Pleural Mesothelioma Epidemiological Insights 

Malignant Pleural Mesothelioma Market Drivers

• Rapidly Evolving Landscape of New Therapeutic Opportunities
• Developments in Diagnosis and Staging
• Rich Emerging Pipeline

Malignant Pleural Mesothelioma Therapies

• MTG201
• Pemetrexed
• Celecoxib
• cisplatin
• pemetrexed
• NGR-hTNF
• Gemcitabine

Malignant Pleural Mesothelioma Key Companies 

• Oncovir, Inc.
• NovoCure Ltd.
• Virttu Biologics Limited
• Aduro Biotech, Inc.
• Eli Lilly and Company
• Kissei Pharmaceutical Co., Ltd. 

Scope of the Malignant Pleural Mesothelioma Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Malignant Pleural Mesothelioma Companies: Oncovir, Inc., NovoCure Ltd., Virttu Biologics Limited, Aduro Biotech, Inc., Eli Lilly and Company, Kissei Pharmaceutical Co., Ltd., and others
• Key Malignant Pleural Mesothelioma Therapies: MTG201, Pemetrexed, Celecoxib, cisplatin, pemetrexed, NGR-hTNF, Gemcitabine, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Migraine Market Dynamics:  Malignant Pleural Mesothelioma market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Malignant Pleural Mesothelioma  Market Access and Reimbursement

Malignant Pleural Mesothelioma Market Barriers

• A decline in the Incidence Rate of Malignant Pleural Mesothelioma
• Failure of Investigational Therapies
• No Clear Regulatory Precedence of Approved Therapies

Table of Contents 

1. Malignant Pleural Mesothelioma Market Report Introduction

2. Executive Summary for Malignant Pleural Mesothelioma

3. SWOT analysis of Malignant Pleural Mesothelioma

4. Malignant Pleural Mesothelioma Patient Share (%) Overview at a Glance

5. Malignant Pleural Mesothelioma Market Overview at a Glance

6. Malignant Pleural Mesothelioma Disease Background and Overview

7. Malignant Pleural Mesothelioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Malignant Pleural Mesothelioma 

9. Malignant Pleural Mesothelioma Current Treatment and Medical Practices

10. Malignant Pleural Mesothelioma Unmet Needs

11. Malignant Pleural Mesothelioma Emerging Therapies

12. Malignant Pleural Mesothelioma Market Outlook

13. Country-Wise Malignant Pleural Mesothelioma Market Analysis (2019–2032)

14. Malignant Pleural Mesothelioma Market Access and Reimbursement of Therapies

15. Malignant Pleural Mesothelioma Market drivers

16. Malignant Pleural Mesothelioma Market barriers

17.  Malignant Pleural Mesothelioma Appendix

18. Malignant Pleural Mesothelioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Malignant Pleural Mesothelioma treatment, visit @ Malignant Pleural Mesothelioma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/